0001802768-23-000032.txt : 20231114
0001802768-23-000032.hdr.sgml : 20231114
20231114193511
ACCESSION NUMBER: 0001802768-23-000032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231113
FILED AS OF DATE: 20231114
DATE AS OF CHANGE: 20231114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lloyd George W.
CENTRAL INDEX KEY: 0001814899
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39329
FILM NUMBER: 231408657
MAIL ADDRESS:
STREET 1: C/O ROYALTY PHARMA PLC
STREET 2: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Royalty Pharma plc
CENTRAL INDEX KEY: 0001802768
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 883-0200
MAIL ADDRESS:
STREET 1: 110 EAST 59TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
wk-form4_1700008499.xml
FORM 4
X0508
4
2023-11-13
0
0001802768
Royalty Pharma plc
RPRX
0001814899
Lloyd George W.
C/O ROYALTY PHARMA PLC
110 EAST 59TH STREET
NEW YORK
NY
10022
0
1
0
0
EVP, Investments & CLO
0
Class A Ordinary Shares
2023-11-13
4
C
0
50000
0
A
80000
I
By GWL 2020 G, LLC
Class A Ordinary Shares
2023-11-13
4
C
0
100000
0
A
220000
I
By GWL 2014 G, LLC
Class A Ordinary Shares
495860
I
By GWL 2013 NG, LLC
Class A Ordinary Shares
273960
I
By IRA
Class A Ordinary Shares
3000
D
Class A Ordinary Shares
4011
I
By Spouse
LP interests in RPI US Partners 2019, LP
0
2023-11-13
4
C
0
5000
0
D
Class A Ordinary Shares
50000
245299
I
By GWL 2020 G, LLC
LP interests in RPI US Partners 2019, LP
0
2023-11-13
4
C
0
10000
0
D
Class A Ordinary Shares
100000
162680
I
By GWL 2014 G, LLC
LP interests in RPI US Partners 2019, LP
0
Class A Ordinary Shares
81730
8173
I
By GWL 2013 NG, LLC
These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.
Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
In addition to the holdings disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold ICAI Interests exchangeable into 2,647,501 Class A Ordinary Shares.
/s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd
2023-11-14